Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety,Tolerance and Efficacy of Neoantigen Targeting T Cells Suspension for Intravenous Infusion(Neo-T) to Advanced Solid Tumor

NCT05798546 is registered in ClinicalTrials.gov with BGI, China as lead sponsor.

NCT NCT05798546
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05798546 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety,Tolerance and Efficacy of Neoantigen Targeting T Cells Suspension for Intravenous Infusion(Neo-T) to Advanced Solid Tumor
Lead sponsor
BGI, China
Phase
Phase 1
Overall status
Unknown status
Start date
September 28, 2022
Completion date
September 30, 2024
Enrollment
21 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor